177 related articles for article (PubMed ID: 36120434)
1. The miR-33a-5p/CROT axis mediates ovarian cancer cell behaviors and chemoresistance
Li X; Gao X; Yuan J; Wang F; Xu X; Wang C; Liu H; Guan W; Zhang J; Xu G
Front Endocrinol (Lausanne); 2022; 13():950345. PubMed ID: 36120434
[TBL] [Abstract][Full Text] [Related]
2. A novel homeostatic loop of sorcin drives paclitaxel-resistance and malignant progression via Smad4/ZEB1/miR-142-5p in human ovarian cancer.
Zhang J; Guan W; Xu X; Wang F; Li X; Xu G
Oncogene; 2021 Jul; 40(30):4906-4918. PubMed ID: 34163033
[TBL] [Abstract][Full Text] [Related]
3. CircATL2 enhances paclitaxel resistance of ovarian cancer via impacting miR-506-3p/NFIB axis.
Ying H; Zhao R; Yu Q; Zhang K; Deng Q
Drug Dev Res; 2022 Apr; 83(2):512-524. PubMed ID: 34541682
[TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.
Li ZY; Wang XL; Dang Y; Zhu XZ; Zhang YH; Cai BX; Zheng L
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):591-603. PubMed ID: 32016960
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.
Feng L; Shen F; Zhou J; Li Y; Jiang R; Chen Y
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32190895
[TBL] [Abstract][Full Text] [Related]
6. Integrative microRNA and gene expression analysis identifies new epigenetically regulated microRNAs mediating taxane resistance in ovarian cancer.
Hassan MK; Waly AA; Elsayed W; Keshk S; Allam WR; El-Khamisy SF
Sci Rep; 2021 Jan; 11(1):562. PubMed ID: 33436648
[TBL] [Abstract][Full Text] [Related]
7. MiR-181c sensitizes ovarian cancer cells to paclitaxel by targeting GRP78 through the PI3K/Akt pathway.
Zhang LY; Yu JY; Leng YL; Zhu RR; Liu HX; Wang XY; Yang TT; Guo YN; Tang JL; Zhang XC
Cancer Gene Ther; 2022 Jun; 29(6):770-783. PubMed ID: 34145425
[TBL] [Abstract][Full Text] [Related]
8. Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer.
Chen Y; Cao XY; Li YN; Qiu YY; Li YN; Li W; Wang H
Am J Physiol Cell Physiol; 2018 Aug; 315(2):C225-C235. PubMed ID: 29719173
[TBL] [Abstract][Full Text] [Related]
9. UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis.
Wang J; Ye C; Liu J; Hu Y
Biochem Biophys Res Commun; 2018 Jul; 501(4):1034-1040. PubMed ID: 29777711
[TBL] [Abstract][Full Text] [Related]
10. F-Box and Leucine-Rich Repeat Protein 20 (FBXL20), Negatively Regulated by microRNA (miR)-195-5p, Accelerates the Malignant Progression of Ovarian Cancer.
Wu D; Liu C; Hong L
Mol Biotechnol; 2021 Dec; 63(12):1235-1243. PubMed ID: 34338995
[TBL] [Abstract][Full Text] [Related]
11. miR-183 modulated cell proliferation and apoptosis in ovarian cancer through the TGF-β/Smad4 signaling pathway.
Zhou J; Zhang C; Zhou B; Jiang D
Int J Mol Med; 2019 Apr; 43(4):1734-1746. PubMed ID: 30720057
[TBL] [Abstract][Full Text] [Related]
12. MiR-34c/SOX9 axis regulates the chemoresistance of ovarian cancer cell to cisplatin-based chemotherapy.
Xiao S; Li Y; Pan Q; Ye M; He S; Tian Q; Xue M
J Cell Biochem; 2019 Mar; 120(3):2940-2953. PubMed ID: 30537410
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of microRNA-195-5p reduces cisplatin resistance and angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent GSK3β/β-catenin signaling pathway.
Dai J; Wei R; Zhang P; Kong B
J Transl Med; 2019 Jun; 17(1):190. PubMed ID: 31171023
[TBL] [Abstract][Full Text] [Related]
14. Lnc00908 promotes the development of ovarian cancer by regulating microRNA-495-5p.
Jiang JN; Hong QY; Gao HJ; Lai BL; Lan JF; Yang Q
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1388-1396. PubMed ID: 30840259
[TBL] [Abstract][Full Text] [Related]
15. Circ_0025033 deficiency suppresses paclitaxel resistance and malignant development of paclitaxel-resistant ovarian cancer cells by modulating the miR-532-3p/FOXM1 network.
Huang H; Yan L; Zhong J; Hong L; Zhang N; Luo X
Immunopharmacol Immunotoxicol; 2022 Apr; 44(2):275-286. PubMed ID: 35196944
[TBL] [Abstract][Full Text] [Related]
16. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
[TBL] [Abstract][Full Text] [Related]
17. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.
Kanlikilicer P; Bayraktar R; Denizli M; Rashed MH; Ivan C; Aslan B; Mitra R; Karagoz K; Bayraktar E; Zhang X; Rodriguez-Aguayo C; El-Arabey AA; Kahraman N; Baydogan S; Ozkayar O; Gatza ML; Ozpolat B; Calin GA; Sood AK; Lopez-Berestein G
EBioMedicine; 2018 Dec; 38():100-112. PubMed ID: 30487062
[TBL] [Abstract][Full Text] [Related]
18. S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.
Lin M; Xia B; Qin L; Chen H; Lou G
DNA Cell Biol; 2018 May; 37(5):491-500. PubMed ID: 29485916
[TBL] [Abstract][Full Text] [Related]
19. MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
Xiao F; Li Y; Wan Y; Xue M
Cancer Chemother Pharmacol; 2018 May; 81(5):935-947. PubMed ID: 29594361
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-133b inhibits proliferation and invasion of ovarian cancer cells through Akt and Erk1/2 inactivation by targeting epidermal growth factor receptor.
Liu X; Li G
Int J Clin Exp Pathol; 2015; 8(9):10605-14. PubMed ID: 26617770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
